XML 47 R31.htm IDEA: XBRL DOCUMENT
v3.26.1

Deconsolidation (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Deconsolidation |
Schedule of Consolidated Balance Sheet | The following table represents the consolidated balance sheet of xXoZymes immediately prior to the Deconsolidation Date (in thousands): Schedule of Consolidated Balance Sheet
|  | December 31, 2024 |
Assets |  |  |  |
Cash and cash equivalents |  | $ | 68 |
Grants receivable |  |  | 701 |
Prepaid expenses and other current assets |  |  | 441 |
Deferred IPO Costs |  |  | 550 |
Property and equipment, net |  |  | 710 |
Operating lease right-of-use asset, net |  |  | 1,366 |
Total assets |  | $ | 3,836 |
Liabilities and Deficit |  |  |  |
Accounts payable |  | $ | 851 |
Accrued expenses |  |  | 241 |
Due to affiliates |  |  | 5,479 |
Deferred grant reimbursement |  |  | 130 |
Operating lease liabilities |  |  | 1,417 |
Total liabilities |  | $ | 8,118 |
Deficit: |  |  |  |
Common shares |  |  | - |
Paid-in-capital |  | $ | 4,120 |
Accumulated deficit |  |  | (8,402 | )
Total deficit |  | $ | (4,282 | )
Total liabilities and deficit |  | $ | 3,836 |
Schedule of Gain on Deconsolidation | The following represents the calculation of the gain on deconsolidation of eXoZymes from the consolidated financial statements of the Company (in thousands, except for share price): Schedule of Gain on Deconsolidation
eXoZymes Class A common shares retained on November 14, 2024 |  |  | 3,931 |
Quoted closing price of eXoZymes Class A common shares at November 14, 2024 |  | $ | 10.36 |
Subtotal of quoted closing price of eXoZymes Class A common shares at November 14, 2024 |  | $ | 40,727 |
Fair value of warrants held for eXoZymes at November 14, 2024 |  |  | 1,327 |
Fair value of equity method investment retained by eXoZymes |  |  | 42,054 |
Carrying Value of the NCI |  |  | (921 | )
Carrying value of eXoZymes assets at November 14, 2024 |  |  | 4,282 |
Less carrying value of former investment into eXoZymes at November 14, 2024 |  |  | (5,787 | )
Carrying value of warrants held for eXoZymes at November 14,2024 |  |  | (321 | )
Gain on deconsolidation |  | $ | 39,307 |

X
- References No definition available. + Details
Name: | MDBH_DisclosureDeconsolidationAbstract
Namespace Prefix: | MDBH_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule Of Gain On Deconsolidation [Table Text Block] + References No definition available. + Details
Name: | MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock
Namespace Prefix: | MDBH_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration